Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone415-374-7782
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$147.70 million
Profitability
Miscellaneous
Employees788
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Wednesday, November, 6th. The medical research company reported ($0.69) EPS for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.17. The medical research company had revenue of $56.51 million for the quarter, compared to analyst estimates of $55 million. InVitae had a negative return on equity of 58.90% and a negative net margin of 99.49%. View InVitae's Earnings History.
When is InVitae's next earnings date?
What price target have analysts set for NVTA?
5 brokerages have issued twelve-month price objectives for InVitae's shares. Their forecasts range from $20.00 to $34.00. On average, they expect InVitae's stock price to reach $29.00 in the next year. This suggests a possible upside of 58.4% from the stock's current price. View Analyst Price Targets for InVitae.
What is the consensus analysts' recommendation for InVitae?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.
What are Wall Street analysts saying about InVitae stock?
Here are some recent quotes from research analysts about InVitae stock:
- 1. According to Zacks Investment Research, "Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California. " (1/16/2020)
- 2. Chardan Capital analysts commented, "We liked the new strategic partnerships with biopharma companies, growth in billable tests, and improvement in average cost per sample during the quarter. We see NVTA as a leader among high-growth digital health companies and we see the stock as mispriced compared with its valuation peers. We see the potential for over 50% upside in the name in the next 12 months as Management executes and the stock trades more in line with its valuation comparable." (6/11/2019)
Has InVitae been receiving favorable news coverage?
Media headlines about NVTA stock have been trending positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. InVitae earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for InVitae.
Are investors shorting InVitae?
InVitae saw a increase in short interest in January. As of January 15th, there was short interest totalling 19,440,000 shares, an increase of 10.8% from the December 31st total of 17,550,000 shares. Based on an average daily trading volume, of 1,860,000 shares, the short-interest ratio is currently 10.5 days. Currently, 20.8% of the company's shares are sold short. View InVitae's Current Options Chain.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).
What other stocks do shareholders of InVitae own?
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 61)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
- Mr. Lee Bendekgey, Sec. & COO (Age 61)
- Ms. Laura D'Angelo, Head of Investor Relations
When did InVitae IPO?
(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who are InVitae's major shareholders?
InVitae's stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.77%), Profit Investment Management LLC (0.19%), K.J. Harrison & Partners Inc (0.02%), Alpine Global Management LLC (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Valeo Financial Advisors LLC (0.00%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which major investors are buying InVitae stock?
NVTA stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, K.J. Harrison & Partners Inc, Alpine Global Management LLC, Profit Investment Management LLC, Valeo Financial Advisors LLC, Exchange Traded Concepts LLC and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $18.31.
How big of a company is InVitae?
InVitae has a market capitalization of $1.77 billion and generates $147.70 million in revenue each year. The medical research company earns $-129,350,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. InVitae employs 788 workers across the globe.View Additional Information About InVitae.
What is InVitae's official website?
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NYSE NVTA)
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
